Pacebo-controlled, double-blind, randomised phase II study withcrossover-design investigating the modulatory effects of intranasalOxytocin on social cognition in patients with Autism-Spectrum-Disorder - Social Cognition-Autism-Oxytocin

开始日期2017-02-01

申办/合作机构

Max-Planck-Institut für Kohlenforschung

DRKS00004572 / CompletedN/AIIT

Treatment of non-fluent aphasia through melody, rhythm and formulaic language

开始日期2010-05-01

申办/合作机构

Max-Planck-Institut für Kohlenforschung

100 项与 Max-Planck-Institut für Kohlenforschung 相关的临床结果

登录后查看更多信息

0 项与 Max-Planck-Institut für Kohlenforschung 相关的专利（医药）

登录后查看更多信息

1,871

项与 Max-Planck-Institut für Kohlenforschung 相关的文献（医药）

2024-12-31·Green Chemistry Letters and Reviews

Breaking down lignin in gamma-valerolactone: advances into a bioelectrorefinery

作者: Rodrigues, Bruno V. M. ; Lindenbeck, Lucie M. ; Schebb, Nils Helge ; Dahlhaus, Sira ; Slabon, Adam ; Wende, Luca M. ; Beele, Björn B. ; Frauscher, Marcella ; Lehmann, Christian W. ; Bornhorst, Julia

This study builds upon our experience with electrocatalyzed dearomatization of lignin in aqueous systems, which has shown to produce sodium levulinate, sodium 4-hydroxyvalerate, sodium acetate, and sodium formate as major products.Here, we extend this investigation by exploring a water/γ-valerolactone (GVL) solvent system for electrochem. depolymerization and dearomatization of lignin, using Na₂CO₃ as electrolyte.GVL, derived from biomass, has frequently been employed for biomass treatment, notably in the Organosolv process.Consequently, various biorefinery strategies have emerged utilizing GVL as a green platform, primarily for its potential in delignifying lignocellulosic biomass when combined with water and dilute acid.This study proposes electrochem. depolymerization of lignin in GVL as a step toward the concept of a bioelectrorefinery, aiming to convert lignin into aliphatic organic chems.Consistent with our prior work in aqueous systems, applying a current of -100 mA over 8 h yielded sodium levulinate, sodium 4-hydroxyvalerate, sodium acetate, and sodium formate.Confirmation was provided by liquid chromatog. electrospray ionization high-resolution mass spectrometry, NMR, and IR spectroscopy.These findings advance our understanding of GVL as a biomass-based platform, highlighting its potential not only for biomass treatment but also as a medium for converting lignin into valuable aliphatic chems.

2024-10-09·Journal of the American Chemical Society

Allenyl Thianthrenium Salt: A Bench-Stable C₃ Synthon for Annulation and Cross-Coupling Reactions

Article

作者: Klask, Nicolai ; Ritter, Tobias ; Tewari, Srija

Herein, we report the first bench-stable and nonhygroscopic monosubstituted allenyl sulfonium salt (ATT) synthesized from thianthrene and propargyl alcohol. We demonstrate its use in annulation chemistry to synthesize heterocycles, such as 2-hydroxy morpholine, 2-methyl quinoxalines, and benzodioxepinone derivatives, with an exocyclic double bond. The reagent is the first allenyl sulfonium salt that can undergo palladium-catalyzed cross-coupling reactions to form a C(sp²)-C(sp²) bond via Suzuki coupling and a C(sp³)-C(sp²) bond formation via reductive coupling.

2024-09-25·Journal of the American Chemical Society

In Situ Observation of Elusive Dirhodium Carbenes and Studies on the Innate Role of Carboxamidate Ligands in Dirhodium Paddlewheel Complexes: A Combined Experimental and Computational Approach

Article

作者: Fürstner, Alois ; Caló, Fabio ; Peeters, Matthias ; Leutzsch, Markus ; Auer, Alexander A. ; Bistoni, Giovanni ; Baldinelli, Lorenzo

Carboxamidates as equatorial ligands in dirhodium paddlewheel catalysts are widely believed to increase selectivity at the expense of reactivity. The results of the combined experimental and computational approach described in this paper show that one has to beware of such generalizations. First, ¹⁰³Rh NMR revealed how strongly primary carboxamidates impact the electronic nature of the rhodium center they are bound to; at the same time, such ligands stabilize donor/acceptor carbenes by engaging their ester carbonyl group into peripheral interligand hydrogen bonding. This array benefits selectivity as well as reactivity if maintained along the entire reaction coordinate of a catalytic cyclopropanation. In settings where the hydrogen bond needs to be distorted for the reaction to proceed, however, it constitutes a significant enthalpic handicap. Representative examples for each scenario were analyzed by DFT; in both cases, the cyclopropanation step rather than carbene formation was found to be turnover-limiting. While this conclusion somehow contradicts the literature, it implied that the direct observation of highly reactive dirhodium carbenes in truly catalytic settings might be possible, even though the intermediates carry olefinic sites amenable to intramolecular cyclopropanation. Such in situ monitoring by NMR is without precedent, yet it was successful with the homoleptic catalyst [Rh₂(OPiv)₄] as well as with its heteroleptic sibling [Rh₂(OPiv)₃(acam)] comprising an acetamidate (acam); in the latter case, the carbene bound to the rhodium atom at the [O₃N]-face was observed, which concurs with the computational data that this species is stabilized by the forecited interligand hydrogen bonding.

项与 Max-Planck-Institut für Kohlenforschung 相关的新闻（医药）

2023-04-20

·BioSpace

Sofinnova Partners Appoints Mary McCarthy as Partner for the Firm’s Industrial Biotech Strategy

McCarthy’s experience and network will help identify early-stage biotech companies developing sustainable solutions in agriculture, food, chemicals, and materials New partner bolsters Sofinnova’s continuing expansion and pioneering role in environmental impact through biotech investments PARIS--(BUSINESS WIRE)-- Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Mary McCarthy as Partner at Sofinnova Partners, joining the growing Sofinnova Industrial Biotech Strategy team. She will use her extensive experience and network to help identify the most promising early-stage companies developing biotech-enabled sustainable solutions in agriculture, food, chemicals, and materials. The Sofinnova Industrial Biotech Strategy has made 24 investments to date and is actively investing out of its third fund of €175M. This press release features multimedia. View the full release here: Mary McCarthy (Photo: Business Wire) Before joining Sofinnova Partners, Mary was a Partner at Brightlands Venture Partners (BVP) where she was the Fund Manager of the BVP Renewable Chemistry Fund and served on various boards. With over 24 years in chemistry and materials, Mary has occupied various roles in the sector: She was CEO of a start-up developing materials for the circular economy and worked at SABIC for 15 years, where she held various functions in R&D, HR, Change Management, and Corporate Venturing. Michael Krel, Partner at Sofinnova Partners, said: "Mary is a perfect addition to our team with broad experience in the venture, start-up and corporate world. This appointment is another step forward in the growth of our industrial biotech strategy; it bolsters our commitment to identifying and supporting early-stage companies that have the potential to develop innovations with strong environmental impact." Joško Bobanović, Partner at Sofinnova Partners, said: "Mary joins our team at an exciting time of growth and evolution of the industrial biotech ecosystem. With her track record of successful investments, Mary will strengthen our capacity to meet the increasing demand for innovative and sustainable solutions for the environment." Mary McCarthy, Partner at Sofinnova Partners, said: "I'm very pleased to join Sofinnova Partners. The Industrial Biotech team is a recognized pioneer in the sector with a wealth of accumulated knowledge. I am looking forward to contributing to the team’s mission of finding deeptech solutions with strong environmental impact that can truly change the world for the better." Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, said: "Mary’s appointment strengthens Sofinnova’s leadership position in industrial biotech and reinforces the work this team has been doing for over a decade in forging a strong platform through investments in sustainability. Industrial biotech is a crucial pillar for the future of our firm, and Mary’s extensive network, ability to recognize disruptive technology, and genuine commitment to make the global economy more sustainable will undoubtedly contribute to accelerating this trajectory." Mary holds a PhD in chemistry from University College Dublin, Ireland and held postdoctoral fellowships at the University of Amsterdam, the Netherlands and the Max Planck Institute für Kohlenforschung, Germany. About Sofinnova Partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com. View source version on businesswire.com: Contacts Bommy Lee Head of Communications Sofinnova Partners blee@sofinnovapartners.com +33 (0) 6 47 71 38 11 North America RooneyPartners LLC Kate Barrette kbarrette@rooneypartners.com +1 212 223 0561 United Kingdom Optimum Strategic Communications Hollie Vile sofinnova@optimumcomms.com +44 (0) 20 3922 0900 France StrategiesImage Anne Rein anne.rein@strategiesimage.com +33 (0) 6 03 35 92 05 Italy Havas PR Milan Pierluigi Cavarai pierluigi.cavaraiext@havaspr.com +39 (0) 392 77 999 Source: Sofinnova Partners Smart Multimedia Gallery Photo Mary McCarthy (Photo: Business Wire) Photo Industrial Biotech Team (Photo: Business Wire) Logo View this news release and multimedia online at:

高管变更

100 项与 Max-Planck-Institut für Kohlenforschung 相关的药物交易

登录后查看更多信息

100 项与 Max-Planck-Institut für Kohlenforschung 相关的转化医学

登录后查看更多信息